Related Experiment Video
Updated: Oct 21, 2025
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Maternal RSV vaccine development. Where to from here?
Ahinsa Gunatilaka1, Michelle L Giles1
1Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.
Insights
Respiratory syncytial virus (RSV) causes significant infant illness and death globally. Maternal RSV vaccination shows promise for protecting vulnerable infants, offering a key prevention strategy.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants worldwide.
- Infant morbidity and mortality due to RSV are disproportionately high in low-income countries and in infants under six months old.
- Currently, no effective treatment exists for RSV infection, making prevention a critical public health priority.
Purpose of the Study:
- To review the current landscape of RSV prevention strategies.
- To highlight maternal RSV vaccination as a promising approach for protecting young infants.
- To discuss the implications of ongoing clinical trial results for public health policy.
Main Methods:
- Review of existing literature on RSV epidemiology and prevention.
- Analysis of the rationale and potential efficacy of maternal RSV vaccination.
- Consideration of public health implementation strategies for RSV vaccines.
Main Results:
- Monoclonal antibodies and vaccines are the primary methods for RSV prevention.
- Maternal vaccination has a strong precedent in protecting infants against other diseases.
- Phase III clinical trial data are crucial for informing vaccine implementation decisions.
Conclusions:
- Maternal RSV vaccination is a highly promising strategy to protect infants during their most vulnerable period.
- The implementation of RSV vaccines requires careful consideration alongside other public health measures.
- Further data from ongoing trials will guide the global strategy for reducing the burden of RSV disease.
Abstract:
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection and is responsible for a large proportion of infant morbidity and mortality worldwide. Most RSV-related deaths occur in children under six months, and the majority of these occur in low-income settings. To date, there is no known efficacious treatment for RSV infection; hence, prevention remains an important strategy to reduce the global burden of disease. Monoclonal antibodies and vaccinations are currently the two main approaches for prevention of RSV disease. Maternal RSV vaccination is of particular interest as a strategy to protect infants during their most vulnerable period as this approach has proven highly efficacious in other vaccine-preventable conditions such as pertussis and influenza. As results from ongoing phase III clinical trials become available, important decisions will need to be made about the priority and potential implementation of RSV vaccines alongside other public health measures.
More Related Videos
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:29Microorganisms in Medicine and Therapeutics